VYGR VOYAGER THERAPEUTICS
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 12 analyst firms say about VOYAGER THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
11 rated views · 12 analyst/firm records · 12 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 4 reports on VYGR from 2 analyst firms in the last 90 days (12 firms in the past year).
Comparing each firm's latest target with its previous one: 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Baird | Jack K Allen | Buy | 1 Jun 2026 | 18.00 USD |
| Canaccord Genuity | Sumant Kulkarni | Buy | 11 May 2026 | 12.00 USD |
| Cantor Fitzgerald | Pete Stavropoulos | Buy | 23 Mar 2026 | — |
| Guggenheim | Debjit Chattopadhyay | Buy | 11 Mar 2026 | 22.00 USD |
| H.C. Wainwright | Patrick Trucchio | Buy | 28 Oct 2026 | 25.00 USD |
| Leerink Partners | Lili Nsongo | Buy | 16 Mar 2026 | 10.00 USD |
| TD Cowen | Philip M Nadeau | Buy | 7 Aug 2026 | — |
| Truist | Unnamed analyst | Buy | 25 Mar 2026 | — |
| Wedbush | Yun Zhong | Buy | 7 Aug 2026 | 8.00 USD |
| Weiss Ratings | Unnamed analyst | — | 9 Oct 2026 | — |
| Wells Fargo | Yanan Zhu | Buy | 8 May 2026 | 10.00 USD |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 08:12 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.